We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Redwire's Microgravity Platform Expand Commercial Opportunities?
Read MoreHide Full Article
Key Takeaways
RDW operates 11 active ISS payload facilities supporting research and manufacturing applications.
RDW's PIL-BOX platform enables pharmaceutical research through protein crystal growth in microgravity.
RDW can receive royalties from pharmaceutical products resulting from its ExesaLibero Pharma agreement.
Redwire Corporation (RDW - Free Report) is expanding its microgravity capabilities to support applications beyond traditional space missions. The company is using the unique conditions of microgravity for scientific research, biotechnology and advanced manufacturing, creating opportunities to develop products and services with potential applications on Earth.
Redwire has built a growing microgravity platform with 11 active payload facilities on the International Space Station as of Dec. 31, 2025. Its capabilities support space-based biotechnology, plant and animal science, in-space additive manufacturing and advanced material manufacturing. The company has also launched 42 Pharmaceutical In-space Laboratory – Bio-crystal Optimization eXperiment (PIL-BOX) payloads.
The pharmaceutical application provides an important avenue for further development. Redwire’s PIL-BOX enables pharmaceutical companies and researchers to use microgravity to grow protein crystals and other key molecules. These conditions can produce differentiated properties that are not comparable to products manufactured on Earth. During 2025, Redwire also entered into a licensing agreement with ExesaLibero Pharma, under which it is eligible to receive royalties from commercial sales of resulting pharmaceutical products.
Redwire’s continued investment in microgravity could broaden its commercial opportunity beyond spacecraft and space infrastructure. By combining established payload capabilities with pharmaceutical and advanced-material applications, the company is building a platform that can support research today while potentially creating additional commercial opportunities as products developed through microgravity applications progress toward commercialization.
Companies Advancing Space-Based Research Capabilities
Growing interest in space-based research and advanced manufacturing is encouraging companies to expand technologies that support scientific and commercial applications in microgravity. Bristol Myers Squibb Company (BMY - Free Report) and Eli Lilly and Company (LLY - Free Report) are also exploring space-based research opportunities that can support pharmaceutical development.
Bristol Myers Squibb has partnered with Redwire on microgravity research, including the use of Redwire’s PIL-BOX platform to study pharmaceutical molecules and crystal growth in space.
Eli Lilly has also partnered with Redwire on PIL-BOX missions, using microgravity conditions to support research involving pharmaceutical molecules and potentially advance drug-development processes.
Earnings Estimates for RDW Stock
The Zacks Consensus Estimate for 2026 and 2027 earnings per share suggests year-over-year growth of 57.32% and 40%, respectively.
Image Source: Zacks Investment Research
RDW Stock Is Trading at a Premium
Redwire is trading at a premium relative to the industry, with a forward 12-month price-to-sales of 4.92X compared with the industry average of 2.29X.
Image Source: Zacks Investment Research
RDW Stock Price Performance
Over the past six months, RDW shares have risen 10% against the industry’s 13.4% fall.
View the Zacks #1 Rank List
Image: Bigstock
Can Redwire's Microgravity Platform Expand Commercial Opportunities?
Key Takeaways
Redwire Corporation (RDW - Free Report) is expanding its microgravity capabilities to support applications beyond traditional space missions. The company is using the unique conditions of microgravity for scientific research, biotechnology and advanced manufacturing, creating opportunities to develop products and services with potential applications on Earth.
Redwire has built a growing microgravity platform with 11 active payload facilities on the International Space Station as of Dec. 31, 2025. Its capabilities support space-based biotechnology, plant and animal science, in-space additive manufacturing and advanced material manufacturing. The company has also launched 42 Pharmaceutical In-space Laboratory – Bio-crystal Optimization eXperiment (PIL-BOX) payloads.
The pharmaceutical application provides an important avenue for further development. Redwire’s PIL-BOX enables pharmaceutical companies and researchers to use microgravity to grow protein crystals and other key molecules. These conditions can produce differentiated properties that are not comparable to products manufactured on Earth. During 2025, Redwire also entered into a licensing agreement with ExesaLibero Pharma, under which it is eligible to receive royalties from commercial sales of resulting pharmaceutical products.
Redwire’s continued investment in microgravity could broaden its commercial opportunity beyond spacecraft and space infrastructure. By combining established payload capabilities with pharmaceutical and advanced-material applications, the company is building a platform that can support research today while potentially creating additional commercial opportunities as products developed through microgravity applications progress toward commercialization.
Companies Advancing Space-Based Research Capabilities
Growing interest in space-based research and advanced manufacturing is encouraging companies to expand technologies that support scientific and commercial applications in microgravity. Bristol Myers Squibb Company (BMY - Free Report) and Eli Lilly and Company (LLY - Free Report) are also exploring space-based research opportunities that can support pharmaceutical development.
Bristol Myers Squibb has partnered with Redwire on microgravity research, including the use of Redwire’s PIL-BOX platform to study pharmaceutical molecules and crystal growth in space.
Eli Lilly has also partnered with Redwire on PIL-BOX missions, using microgravity conditions to support research involving pharmaceutical molecules and potentially advance drug-development processes.
Earnings Estimates for RDW Stock
The Zacks Consensus Estimate for 2026 and 2027 earnings per share suggests year-over-year growth of 57.32% and 40%, respectively.
Image Source: Zacks Investment Research
RDW Stock Is Trading at a Premium
Redwire is trading at a premium relative to the industry, with a forward 12-month price-to-sales of 4.92X compared with the industry average of 2.29X.
Image Source: Zacks Investment Research
RDW Stock Price Performance
Over the past six months, RDW shares have risen 10% against the industry’s 13.4% fall.
Image Source: Zacks Investment Research
RDW’s Zacks Rank
Redwire currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.